Indication
Thrombocythemia
4 clinical trials
3 products
Clinical trial
A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2024-08-22
Product
BomedemstatClinical trial
A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib MonotherapyStatus: Completed, Estimated PCD: 2023-08-24
Product
itacitinibClinical trial
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical StudyStatus: Recruiting, Estimated PCD: 2034-12-04
Clinical trial
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)Status: Recruiting, Estimated PCD: 2024-01-01
Product
IMG-7289